Alzecure enters collaboration and with Lilly for Alzheimer’s project
Partnership grants Lilly global rights to Alzstatin ACD680
Read More
Author: John Pinching
Survodutide trial data show targeted visceral and liver fat reductions
Phase 3 results highlight metabolic benefits alongside weight loss
Read More
First patient enrolled in German real‑world study of Pepaxti
Treatment set to be used in routine multiple myeloma care
Read More
Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
Late‑breaking EULAR results highlight sustained responses through week 52
Read More
European approval enables measles protection with CSL’s immunoglobulin Privigen
Commission authorisation expands access to passive measles prophylaxis for vulnerable patients
Read More- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
